A. Palmer
St Mary's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by A. Palmer.
American Journal of Transplantation | 2006
Richard Borrows; G. Chusney; M. Loucaidou; A. James; J. Lee; Jen Van Tromp; J. Owen; Thomas Cairns; M. Griffith; Nadey S. Hakim; A. McLean; A. Palmer; V. Papalois; David Taube
Studies of renal transplantation utilizing trough plasma level monitoring of mycophenolic acid (MPA) have shown inconsistent associations with toxicity and rejection.
American Journal of Transplantation | 2004
Richard Borrows; Marina Loucaidou; Jen Van Tromp; Tom Cairns; M. Griffith; Nadey S. Hakim; A. McLean; A. Palmer; V. Papalois; David Taube
Evidence suggests that steroid sparing in renal transplantation is associated with good outcomes, although there are limited data regarding steroid sparing in Tacrolimus and Mycophenolate Mofetil (MMF)‐based regimes. In this study we describe the use of these agents in 101 consecutive patients undergoing renal transplantation using only a 7‐day course of prednisolone.
Nephron Clinical Practice | 2004
Ajay Dhaygude; M. Griffith; Thomas Cairns; A. McLean; A. Palmer; David Taube
Background: Cyclophosphamide has transformed the outcome of ANCA-associated vasculitis, but it is highly toxic. Recent studies have suggested that pulsed intravenous cyclophosphamide (pCyc) is an effective alternative with less complications, but may lead to an increased rate of relapse. However, these studies used relatively short courses of treatment with cyclophosphamide. In this study we used a prolonged course of low-dose intravenous cyclophosphamide for 18–24 months for ANCA-associated vasculitis, evaluated the effectiveness of pCyc and analysed the outcome of a prolonged treatment on the rate of relapse. Methods: A retrospective analysis of all the patients treated with pCyc from 1995 to 2002 was performed. Results: Thirty-seven patients were followed for an average of 38 months. Thirty-four of 37 patients (91.9%) achieved complete remission at 3 months. Eight (21%) episodes of relapse occurred in 7 patients. The cyclophosphamide was well tolerated with a low rate of infections (18.9%) and 1 death (2.7%) due to sepsis whilst on cyclophosphamide. Conclusion: In this study, pCyc was effective in achieving rapid remission and had a low complication rate. If prolonged, this treatment may reduce the rate of relapse.
Nephrology Dialysis Transplantation | 2004
Neill Duncan; Ajay Dhaygude; Jane Owen; Thomas Cairns; M. Griffith; A. McLean; A. Palmer; David Taube
Transplantation Proceedings | 2005
M. Loucaidou; J. Stitchbury; J. Lee; R. Borrows; Sara E. Marshall; A. McLean; Thomas Cairns; M. Griffith; Nadey S. Hakim; A. Palmer; V. Papalois; K. Welsh; David Taube
Transplantation Proceedings | 2001
W McKane; C Kanganas; R Preston; T Cairns; Nadey S. Hakim; A. Palmer; David Taube
Transplantation Proceedings | 2005
R. Borrows; G. Chusney; M. Loucaidou; S. Singh; A. James; Jose Stichbury; J. Van Tromp; Thomas Cairns; M. Griffith; Nadey S. Hakim; A. McLean; A. Palmer; V. Papalois; David Taube
Transplantation Proceedings | 2001
S Fluck; R Preston; W McKane; A Harris; R Morgan; Wladyslaw Gedroyc; T Cairns; A. Palmer; David Taube
Transplantation Proceedings | 2005
M. Loucaidou; R. Borrows; Thomas Cairns; M. Griffith; Nadey S. Hakim; A. Palmer; V. Papalois; David Taube; A. McLean
Transplant International | 2001
René W. S. Chang; Susan Snowden; A. Palmer; Jonathan T. C. Kwan; Michael L. Nicholson; S. Habib Kashi; Ossie N. Fernando; Ferenc Perner; Guy H. Neild